OOIR: Observatory of International Research

Papers

(The TQCC of Expert Review of Hematology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
D-dimer level in COVID-19 infection: a systematic review	226
Genetic risk factors for venous thromboembolism	47
Evidence-based indications of platelet-rich plasma therapy	44
Autoimmune hemolytic anemia in adults: primary risk factors and diagnostic procedures	37
A review of FDA-approved acute myeloid leukemia therapies beyond ‘7 + 3’	30
Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia	29
Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits	24
Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians	23
COVID-19 associated with immune thrombocytopenia: a systematic review and meta-analysis	23
The biology and management of dyskeratosis congenita and related disorders of telomeres	21
Complement activation and coagulopathy - an ominous duo in COVID19	20
Therapeutic options for steroid-refractory acute and chronic GVHD: an evolving landscape	20
Recent real-world treatment patterns and outcomes in US patients with relapsed/refractory multiple myeloma	20
Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia	20
Platelets: the point of interconnection among cancer, inflammation and cardiovascular diseases	18
Avapritinib for Systemic Mastocytosis	18
Monoclonal antibodies in relapsed/refractory myeloma: updated evidence from clinical trials, real-life studies, and meta-analyses	18
Real-world effectiveness of voxelotor for treating sickle cell disease in the US: a large claims data analysis	18
Safety of FLT3 inhibitors in patients with acute myeloid leukemia	17
The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas	17
The spectrum of beta-thalassemia mutations in the 22 Arab countries: a systematic review	17
Prophylaxis for hemophilia A without inhibitors: treatment options and considerations	17
Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors	15
Hemostatic defects in massive transfusion: an update and treatment recommendations	15
Managing patients with hematological malignancies during COVID-19 pandemic	15

Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia	15
Hematological manifestations and complications of Gaucher disease	14
Voxelotor for the treatment of sickle cell disease	13
Diagnostic and therapeutic challenges in hairy cell leukemia-variant: where are we in 2021?	13
Heparin-induced thrombocytopenia: pathophysiology, diagnosis and treatment	13
Apoptosis targeted therapies in acute myeloid leukemia: an update	13
MRI detection of brain abnormality in sickle cell disease	12
Immune thrombocytopenia	12
Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical development	12
Improving outcomes and quality of life for patients with transfusion-dependent β-thalassemia: recommendations for best clinical practice and the use of novel treatment strategies	12
Transplant-associated thrombotic microangiopathy: elucidating prevention strategies and identifying high-risk patients	12
Screening tools for hereditary hemolytic anemia: new concepts and strategies	11
Moving on from 2013 to 2020 European LeukemiaNet recommendations for treating chronic myeloid leukemia: what has changed over the 7 years?	11
Renal disease associated with chronic myeloproliferative neoplasms	11
Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review	11
Glucose-regulated protein 78 (GRP78) as a potential novel biomarker and therapeutic target in multiple myeloma	11
Evolution of the role of haploidentical stem cell transplantation: past, present, and future	11
Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma	11
Biomarkers for acute and chronic graft versus host disease: state of the art	10
COVID-19 in benign hematology: emerging challenges and special considerations for healthcare professionals	10
Pharmacological management of rare coagulation factor deficiencies besides hemophilia	10
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for mucocutaneous bleeding disorders	10
Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie’s choice for patients with relapsed refractory multiple myeloma	10
What is the future of patient-reported outcomes in sickle-cell disease?	10
Sickle cell disease as a vascular disorder	10
Enhancing CAR T cell efficacy: the next step toward a clinical revolution?	10
Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies	9
Rectal colonization with multidrug-resistant gram-negative bacteria in patients with hematological malignancies: a prospective study	9
Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia	8
Therapeutic strategies, including allogeneic stem cell transplantation, to overcome relapsed/refractory adult T-cell acute lymphoblastic leukemia	8
Immunodeficiency-associated Hodgkin lymphoma	8
Targeting CD123 in BPDCN: an emerging field	8
Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?	8
Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies	8
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: facilitating research through infrastructure, workforce, resources and funding	8
Overcoming the challenges of treating hemophilia in resource-limited nations: a focus on medication access and adherence	8
The advantages and risks of ruxolitinib for the treatment of polycythemia vera	8
A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura	8
Newly diagnosed multiple myeloma: current treatment strategies, emerging therapeutic approaches and beyond	7
Recent guidelines for high-dose chemotherapy and autologous stem cell transplant for systemic AL amyloidosis: a practitioner’s perspective	7
Acute chest syndrome of sickle cell disease: genetics, risk factors, prognosis, and management	7
A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma	7
What COVID-19 can mean for people with hemophilia beyond the infection risk	7
Cardiotoxicity of BTK inhibitors: ibrutinib and beyond	7
Identification and management of fetal anemia due to hemolytic disease	7
Efficacy and safety of thrombopoietin receptor agonists in the treatment of thrombocytopenia after hematopoietic stem cell transplantation: a meta-analysis and systematic review	7
Emerging pharmacotherapies for elderly acute myeloid leukemia patients	7
CD123-targeted therapy in acute myeloid leukemia	7
The National Hemophilia Foundation State of the Science Research Summit initiative: executive summary	7
Association of tuberculosis in patients with chronic myeloid leukemia: a treatment proposal based on literature review	7

Exercise and anemia in cancer patients: could it make the difference?	7
Chronic lymphocytic leukemia prognostic models in real life: still a long way off	7
Post-COVID-19 hematologic complications: a systematic review	7
Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia	7
Applying World Health Organization 2020 guidelines on physical activity and sedentary behavior to people with hemophilia	6
Complications of hemophilia in the elbow: current management	6
Analysis of Hb levels and degree of anemia in relation to genotype in 615 patients with hemoglobin H disease	6
Cardiovascular involvement in patients affected by multiple myeloma: a comprehensive review of recent advances	6
Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice	6
Palliative care for patients with hematologic malignancies: are we meeting patients’ needs early enough?	6
The role of platelets, neutrophils and endothelium in COVID-19 infection	6
Hematopoietic stem cell transplantation for classical inherited bone marrow failure syndromes: an update	6
A critical evaluation of crizanlizumab for the treatment of sickle cell disease	6
A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma	6
A review of current induction strategies and emerging prognostic factors in the management of children and adolescents with acute lymphoblastic leukemia	6
The value of the red cell distribution width index versus other parameters in the differentiation between iron deficiency anemia and beta thalassemia trait among children in Mosul, Iraq	6
Copper deficiency, a rare but correctable cause of pancytopenia: a review of literature	6
Advances in the treatment of thrombotic thrombocytopenic purpura: repurposed drugs and novel agents	6
Chronic neutropenia: how best to assess severity and approach management?	6
Current approaches in the treatment of catheter-related deep venous thrombosis in children	6
Resource limited centres can deliver treatment for children with acute lymphoblastic leukaemia with risk-stratified minimal residual disease based UKALL 2003 protocol with no modification and a good o	6
Extended post-discharge thromboprophylaxis in hospitalized COVID-19 patients	6
Best practices and recommendations for drug regimens and plasma exchange for immune thrombotic thrombocytopenic purpura	6
Hemophilic arthropathy: a teaching approach devoted to hemophilia treaters in under-development countries	6
Consanguineous marriage and rare bleeding disorders	6
Efficacy and safety of front-line treatments for advanced Hodgkin lymphoma: a systematic literature review	6
Developments in identifying and managing mucormycosis in hematologic cancer patients	6
Construction of a DLBCL Prognostic Signature Based on Tumor Microenvironment	5
Outcomes and long-term effects of hematopoietic stem cell transplant in sickle cell disease	5
Venetoclax for the treatment of elderly or chemotherapy-ineligible patients with acute myeloid leukemia: a step in the right direction or a game changer?	5
Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside	5
Pralatrexate injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma	5
Hematopoietic cell transplantation during COVID-19 pandemic: experience from a tertiary hospital in Madrid	5
Immunomodulators in newly diagnosed multiple myeloma: current and future concepts	5
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities to transform the care of people with hemophilia	5
Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?	5
Selinexor for the treatment of patients with previously treated multiple myeloma	5
Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors	5
Evolution of viscoelastic coagulation testing	5
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for ultra-rare inherited bleeding disorders	5
The clinical management of factor XI deficiency in pregnant women	5
Total knee arthroplasty in hemophilia: lessons learned and projections of what’s next for hemophilic knee joint health	5
An evaluation of ferric derisomaltose as a treatment for anemia	5
Optimizing outcomes for haploidentical hematopoietic stem cell transplantation in severe aplastic anemia with intensive GVHD prophylaxis: a review of current findings	5
How low risk are low risk myelodysplastic syndromes?	5